skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis

Review

(2824) Views  (887) Full article downloads

Authors: Paula Rackoff

Published Date May 2009 Volume 2009:4 Pages 207 - 213
DOI: http://dx.doi.org/10.2147/CIA.S4080

Paula Rackoff

Division of Rheumatology, Beth Israel Medical Center, New York, NY, USA

Abstract: Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poor compliance with medications. Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate can reduce vertebral, nonvertebral, and hip fracture incidence in postmenopausal women, in men, and in subsets of older patients at great risk of falls and fragility. The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed.

Keywords: osteoporosis, fracture








Readers of this article also read:

Angioid streaks, clinical course, complications, and current therapeutic management
Diagnosis and management of osteoporosis in the older senior
Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Management of glucocorticoids-induced osteoporosis: role of teriparatide
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Research methodological issues in evaluating herbal interventions
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
Clinicoradiological features of recurrent ischemic stroke: healthcare for poststroke patients
Potential treatment options and future research to increase hepatitis C virus treatment response rate